Advanced Solid Tumors Clinical Trials in Guangzhou, Guangdong
31 recruitingGuangzhou, Guangdong, China
Showing 1–20 of 31 trials
Recruiting
Phase 1
A Study of BG-C477 in Participants With Advanced Solid Tumors
Advanced Solid Tumors
BeOne Medicines310 enrolled32 locationsNCT06596473
Recruiting
Phase 1Phase 2
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
Ovarian CancerPancreatic CarcinomaAdvanced Solid Tumors+1 more
Evopoint Biosciences Inc.350 enrolled24 locationsNCT06799637
Recruiting
Phase 1Phase 2
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Metastatic Solid TumorsLocally Advanced Solid Tumors
Turning Point Therapeutics, Inc.500 enrolled165 locationsNCT03093116
Recruiting
Phase 1
A Study of HS-20122 in Patients With Advanced Solid Tumors
Advanced Solid Tumors
Hansoh BioMedical R&D Company1,050 enrolled1 locationNCT06927570
Recruiting
Phase 1Phase 2
A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.
Advanced Solid Tumors
Shanghai Pharmaceuticals Holding Co., Ltd63 enrolled16 locationsNCT05944224
Recruiting
Phase 1Phase 2
A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors
Advanced Solid Tumors
Suzhou Forlong Biotechnology Co., Ltd130 enrolled1 locationNCT07131202
Recruiting
Phase 1
HW071021 Monotherapy in Patients With Advanced Solid Tumors
Advanced Solid Tumors
Wuhan Humanwell Innovative Drug Research and Development Center Limited Company76 enrolled1 locationNCT06882135
Recruiting
Phase 1Phase 2
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.876 enrolled1 locationNCT06703177
Recruiting
Phase 1Phase 2
A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation
Advanced Solid Tumors CancerPDACCRC (Colorectal Cancer)
Genfleet Therapeutics (Shanghai) Inc.126 enrolled4 locationsNCT07259590
Recruiting
Phase 1Phase 2
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Advanced Solid Tumors
DualityBio Inc.862 enrolled107 locationsNCT05914116
Recruiting
Phase 1Phase 2
A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
Advanced Solid TumorsKRAS G12D Mutations
Genfleet Therapeutics (Shanghai) Inc.407 enrolled20 locationsNCT06500676
Recruiting
Phase 1Phase 2
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.260 enrolled1 locationNCT07208773
Recruiting
Phase 1Phase 2
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Breast CancerAdvanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.414 enrolled20 locationsNCT07169994
Recruiting
Phase 1Phase 2
Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors
Advanced Solid Tumors Harboring NTRK FusionPrimary Central Nervous System Tumors Harboring NTRK Fusion
Beijing InnoCare Pharma Tech Co., Ltd.70 enrolled1 locationNCT05745623
Recruiting
Phase 1
A Study of AK146D1 for Injection in Advanced Solid Tumors
Advanced Solid Tumors
Akeso200 enrolled1 locationNCT07067567
Recruiting
Phase 1Phase 2
A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors
Advanced Solid Tumors
Bio-Thera Solutions216 enrolled1 locationNCT06376136
Recruiting
Early Phase 1
AMT-676 in Patients With Advanced Solid Tumors
Advanced Solid Tumors
Multitude Therapeutics Inc.24 enrolled13 locationsNCT06400485
Recruiting
Phase 1
A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors
Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.162 enrolled30 locationsNCT06394414
Recruiting
Phase 1
A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies
Advanced Solid TumorsHematological Malignancies
Hangzhou DAC Biotechnology Co., Ltd.110 enrolled1 locationNCT06224855
Recruiting
Phase 1
Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies
Advanced Solid Tumors and Hematologic Malignancies
Beijing InnoCare Pharma Tech Co., Ltd.146 enrolled3 locationsNCT05690581